• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对十名健康志愿者进行的低分子量肝素(达肝素200 IU抗Xa/kg)每日一次治疗剂量的时辰药理学研究。

Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.

作者信息

Mismetti P, Reynaud J, Tardy-Ponce B, Laporte-Simitsidis S, Scully M, Goodwyn C, Queneau P, Decousus H

机构信息

Saint-Etienne Thrombosis Research Group, CHU Saint-Etienne, France.

出版信息

Thromb Haemost. 1995 Aug;74(2):660-6.

PMID:8585003
Abstract

Low molecular weight heparin (LMWH) is currently prescribed for the treatment of deep vein thrombosis at the dose of 100 IU antiXa/kg twice daily or at a dose of 175 IU antiXa/kg once daily with a similar efficacy. We decided to study the chrono-pharmacology of curative dose of LMWH once daily administrated according to the one previously described with unfractionated heparin (UFH). Ten healthy volunteers participated in an open three-period crossover study according to three 24 h cycles, separated by a wash-out interval lasting 7 days: one control cycle without injection, two cycles with subcutaneous injection of 200 IU antiXa/kg of Dalteparin (Fragmin) at 8 a.m. or at 8 p.m. Parameters of heparin activity were analysed as maximal values and area under the curve. Activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT) and tissue factor pathway inhibitor (TFPI) were higher after 8 p.m. injection than after 8 a.m. injection (p < 0.05) while no chrono-pharmacological variation of anti factor Xa (AXa) activity was observed. Thus the biological anticoagulant effect of 200 IU antiXa/kg of Dalteparin seems to be higher after an evening injection than after a morning injection. A chrono-therapeutic approach with LMWH, as prescribed once daily, deserves further investigation since our results suggest that a preferential injection time may optimise the clinical efficacy of these LMWH.

摘要

低分子量肝素(LMWH)目前用于治疗深静脉血栓形成,剂量为每日两次,每次100 IU抗Xa/kg,或每日一次,剂量为175 IU抗Xa/kg,疗效相似。我们决定按照先前描述的普通肝素(UFH)的方法,研究每日一次给予LMWH治疗剂量的时辰药理学。10名健康志愿者参与了一项开放的三周期交叉研究,按照三个24小时周期进行,周期之间有7天的洗脱期:一个无注射的对照周期,两个皮下注射周期,分别在上午8点或晚上8点注射200 IU抗Xa/kg的达肝素(法安明)。分析肝素活性参数的最大值和曲线下面积。晚上8点注射后活化部分凝血活酶时间(APTT)、凝血酶时间(TT)、凝血酶原时间(PT)和组织因子途径抑制剂(TFPI)高于上午8点注射后(p<0.05),而抗Xa因子(AXa)活性未观察到时辰药理学变化。因此,200 IU抗Xa/kg达肝素的生物抗凝作用似乎在晚上注射后高于上午注射后。由于我们的结果表明,优先注射时间可能会优化这些LMWH的临床疗效,因此每日一次给药的LMWH时辰治疗方法值得进一步研究。

相似文献

1
Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteers.对十名健康志愿者进行的低分子量肝素(达肝素200 IU抗Xa/kg)每日一次治疗剂量的时辰药理学研究。
Thromb Haemost. 1995 Aug;74(2):660-6.
2
Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.低分子量肝素(速碧林)与普通肝素对体内血栓形成部位凝血激活的影响。
Thromb Haemost. 1994 Dec;72(6):831-5.
3
Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.肝素治疗期间组织因子途径抑制物的血管内释放及尿排泄
J Lab Clin Med. 2004 Nov;144(5):246-53; discussion 226-7. doi: 10.1016/j.lab.2004.08.001.
4
Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.关于鱼精蛋白对人凝血系统激活部位的普通肝素和低分子量肝素(速避凝)的中和作用的研究。
Thromb Haemost. 1995 Mar;73(3):439-43.
5
Comparison of the pharmacokinetic profiles of three low molecular mass heparins--dalteparin, enoxaparin and nadroparin--administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism).三种低分子质量肝素(达肝素、依诺肝素和那屈肝素)在健康志愿者中皮下注射给药(预防血栓栓塞的剂量)的药代动力学特征比较。
Thromb Haemost. 1995 Apr;73(4):630-40.
6
Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.吸入性低分子量肝素克赛在健康受试者中的抗凝作用。
J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):603-14.
7
The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.给予低分子量肝素后,健康犬血浆抗Xa因子活性与止血试验之间的相关性。
Res Vet Sci. 2000 Dec;69(3):241-7. doi: 10.1053/rvsc.2000.0418.
8
Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.Xa因子抑制与凝血活性——达肝素延长治疗及性别对急性冠脉综合征患者和健康个体的影响
Am Heart J. 2008 Mar;155(3):493.e1-8. doi: 10.1016/j.ahj.2007.12.006.
9
Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.单次皮下注射低剂量肝素或低分子量肝素 - 双氢麦角胺组合后的纤溶和抗凝活性。
Thromb Haemost. 1988 Jun 16;59(3):388-91.
10
A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers.健康志愿者中三种低分子量肝素(LMWH)与普通肝素(UH)的对比研究。
Thromb Haemost. 1995 Mar;73(3):398-401.

引用本文的文献

1
Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism.每日一次与每日两次低分子量肝素用于静脉血栓栓塞症的初始治疗
Cochrane Database Syst Rev. 2013 Jul 16;2013(7):CD003074. doi: 10.1002/14651858.CD003074.pub3.